Adicet Bio, Inc. announced a one-for-16 reverse stock split of its common stock.
The reverse stock split will take effect on December 30, 2025.
This move aims to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Reverse Stock Split
One-for-16 reverse stock split approved by the board of directors.
Effective Date
The reverse stock split will be effective on December 30, 2025.
Compliance Objective
Intended to help Adicet regain compliance with Nasdaq listing standards.
- The reverse stock split will reduce the outstanding shares from 153.3 million to approximately 9.6 million.
- No fractional shares will be issued, and adjustments will be made to warrants and equity incentive plans.
- Stockholders are not required to take action as the split-adjusted shares will reflect in their accounts.
Adicet Bio's strategic reverse stock split decision demonstrates commitment to maintaining Nasdaq listing standards and potentially attracting more investors.